- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Serum Institute CEO says vaccine development is like rollercoaster
New Delhi: Adar Poonawalla, CEO, Serum Institute of India (SII), said on Thursday that developing a vaccine is like a rollercoaster ride with ups and downs.
"Developing a vaccine is like riding a rollercoaster; there are plenty of ups and downs. Sometimes we fail, sometimes we succeed, but we must be patient and not jump to conclusions too early. We must wait for all phase 3 trials to be completed," Poonawalla said in a tweet.
There have been reports that one of the strong candidates for a potential vaccine for Covid-19 being tested by researchers at the Oxford University has failed to protect monkeys from being infected by the virus. However, the potential vaccine helped to protect the monkeys from pneumonia.
Reports of the Oxford vaccine's performance on monkeys had prompted researchers to test the vaccine's potency in humans.
The potential of the vaccine had also led to the Serum Institute announcing plans to manufacture four to five million doses in India. It is one of seven global companies that will manufacture the vaccine being developed by the Oxford Vaccine Group.
Read also: AstraZeneca receives 1 Billion USD investment for Oxford vaccine
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.